摘要
目的探讨联合检测血清肿瘤标记物CEA、NSE、CYFRA21-1、ProGRP在肺癌临床诊断中的价值。方法应用酶联免疫法检测62例肺癌病人、21例肺良性病变病人及20例正常健康人的血清中CEA、NSE、CYFRA21-1、ProGRP的水平。结果肺癌组血清4项肿瘤标记物含量均高于肺良性病变组及正常组;CEA在肺腺癌中的水平最高,可达88.9%,CYFRA21-1在肺鳞癌中的水平最高,为68.6%。4项联合检测肺鳞癌、肺腺癌敏感性可分别达88.6%、96.3%。结论运用联合检测多种肿瘤标记物可以提高肺癌诊断的敏感性,同时对鉴别病理类型具有一定的意义。
Objective To study the clinical validity of combined measurement of tumor markers in diagnostic evaluation of lung cancer.Methods Serum levels of CEA,NSE,CYFRA21-1,ProGRP were measured by ELISA in 62 patients with lung cancer,21 patients with benign pulmonary diseases and 20 healthy subjects and analyzed.Results The levels of CEA,NSE,CYFRA21-1,ProGRP in lung cancer patients were significantly higher than that in patients with benign pulmonary diseases and healthy subjects.The patients with pulmonary adenocarcinoma had the highest levels（88.9%）,patients with lung squamous cell carcinoma had the highest levels（68.6%）.The positive rate of the combined measurement of CEA,NSE,CYFRA21-1,ProGRP for lung squamous cell carcinoma,adenocarcinoma were（88.6%）and（96.3%） respectively.Conclusion Combined measurement of multiple serum tumor markers significantly increases the diagnosis sensitivity.In addition,it also has significance to distinguish the pathologic category.
出处
《青岛医药卫生》
2008年第3期161-163,共3页
Qingdao Medical Journal
关键词
肺肿瘤
肿瘤标记物
诊断
联合检测
Lung neoplasms
Tumor markers
Diagnosis
Combined measurement
